CCR4 and neoplasm: We have also shown that co-injection of compound 22, a CCR4 antagonist, with cancer vaccines inhibits Treg cell recruitment into vaccination sites and Treg-mediated DC suppression, resulting in enhanced induction of tumor-specific CTLs in a murine melanoma model [176].